The use of cell lines or animal models has significant disadvantages when dealing with a set of heterogeneous diseases such as epithelial ovarian cancer. This has clinical relevance in that biomarkers developed using cell line or animal models are often not transferable to the clinical setting. In this study, we describe the development of a robust protocol for developing primary cultures of ovarian cancer which will overcome some of these difficulties. Women undergoing surgery for ovarian cancer were recruited and samples of ascites and solid tumour deposits were used to develop primary cultures. Cells were characterised using a panel of immunofluorescent antibodies prior to use in a variety of assays including functional assessment of DNA repair pathways. During the four year study period, viable cultures, confirmed to be epithelial in origin were generated from 156 of 172 (91%) cases recruited. Characterisation was carried out using a panel of antibodies including pancytokeratin, CA125, EpCAM, MOC-31, D2-40 and vimentin. Senescence occurred between the 2nd and 8th passages in all cultures except one in which spontaneous immortalization occurred. Cells could be successfully cultured even after a period of storage at 4°C and cultured cells were capable of being used for a variety of applications including functional assays. Upon functional assessment there was minimal intra-tumour heterogeneity. It is therefore possible to derive viable ovarian cancer cell cultures in the majority of patients undergoing surgery. Cells cultured directly from patient cancers provide an accurate and highly diverse model.
References
[1]
Statistics NOf (2011) Mortality statistics: Deaths registered in 2010 (Series DR) Table 5.2. National Office for Statistics.
[2]
Parmar MK, Ledermann JA, Colombo N, du Bois A, Delaloye JF, et al. (2003) Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 361: 2099–2106. doi: 10.1016/s0140-6736(03)13718-x
[3]
Korch C, Spillman MA, Jackson TA, Jacobsen BM, Murphy SK, et al. (2012) DNA profiling analysis of endometrial and ovarian cell lines reveals misidentification, redundancy and contamination. Gynecol Oncol 127: 241–248. doi: 10.1016/j.ygyno.2012.06.017
[4]
Dunfield LD, Shepherd TG, Nachtigal MW (2002) Primary culture and mRNA analysis of human ovarian cells. Biol Proced Online 4: 55–61. doi: 10.1251/bpo34
[5]
Mukhopadhyay A, Elattar A, Cerbinskaite A, Wilkinson SJ, Drew Y, et al. (2010) Development of a functional assay for homologous recombination status in primary cultures of epithelial ovarian tumor and correlation with sensitivity to poly(ADP-ribose) polymerase inhibitors. Clin Cancer Res 16: 2344–2351. doi: 10.1158/1078-0432.ccr-09-2758
[6]
Le Page C, Ouellet V, Madore J, Ren F, Hudson TJ, et al. (2006) Gene expression profiling of primary cultures of ovarian epithelial cells identifies novel molecular classifiers of ovarian cancer. Br J Cancer 94: 436–445.
[7]
Hennessy BT, Murph M, Nanjundan M, Carey M, Auersperg N, et al. (2008) Ovarian cancer: linking genomics to new target discovery and molecular markers-the way ahead. Adv Exp Med Biol 617: 23–40. doi: 10.1007/978-0-387-69080-3_3
[8]
Hirte HW, Clark DA, Mazurka J, O′Connell G, Rusthoven J (1992) A rapid and simple method for the purification of tumor cells from ascitic fluid of ovarian carcinoma. Gynecol Oncol 44: 223–226. doi: 10.1016/0090-8258(92)90046-l
[9]
Shepherd TG, Theriault BL, Campbell EJ, Nachtigal MW (2006) Primary culture of ovarian surface epithelial cells and ascites-derived ovarian cancer cells from patients. Nat Protoc 1: 2643–2649. doi: 10.1038/nprot.2006.328
[10]
Lee EC (1991) Cytogenetic analysis of continuous cell lines In The ACT Cytogenetic Laboratory Manual: 107-148.
[11]
Vichai V, Kirtikara K (2006) Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat Protoc 1: 1112–1116. doi: 10.1038/nprot.2006.179
[12]
Abramoff M, Magelhaes P, Ram S (2004) Image processing with ImageJ. Biophoton Int 11: 36–42.
[13]
Znojek P (2011) PhD Thesis. Newcastle University.
[14]
Bau DT, Mau YC, Ding SL, Wu PE, Shen CY (2007) DNA double-strand break repair capacity and risk of breast cancer. Carcinogenesis 28: 1726–1730. doi: 10.1093/carcin/bgm109
[15]
Ohashi A, Zdzienicka MZ, Chen J, Couch FJ (2005) Fanconi anemia complementation group D2 (FANCD2) functions independently of BRCA2- and RAD51-associated homologous recombination in response to DNA damage. J Biol Chem 280: 14877–14883. doi: 10.1074/jbc.m414669200
[16]
Perez RP, Godwin AK, Handel LM, Hamilton TC (1993) A comparison of clonogenic, microtetrazolium and sulforhodamine B assays for determination of cisplatin cytotoxicity in human ovarian carcinoma cell lines. Eur J Cancer 29A: 395–399. doi: 10.1016/0959-8049(93)90394-u
[17]
Fong M, Kakar S (2009) Ovarian cancer mouse models: a summary of current models and their limitations. J Ovarian Res 2.
[18]
Bowtell DDL (2010) The genesis and evolution of high-grade serous ovarian cancer. Nat Rev Cancer 10: 803–808. doi: 10.1038/nrc2946
[19]
Khalique L, Ayhan A, Weale ME, Jacobs IJ, Ramus SJ, et al. (2007) Genetic intra-tumour heterogeneity in epithelial ovarian cancer and its implications for molecular diagnosis of tumours. The Journal of Pathology 211: 286–295. doi: 10.1002/path.2112
[20]
Abelson S, Shamai Y, Berger L, Shouval R, Skorecki K, et al. (2012) Intratumoral Heterogeneity in the Self-Renewal and Tumorigenic Differentiation of Ovarian Cancer. STEM CELLS 30: 415–424. doi: 10.1002/stem.1029
[21]
Kobel M, Turbin D, Kalloger S, Gao D, Huntsman D, et al. (2011) Biomarker expression in pelvic high-grade serous carcinoma: comparison of ovarian and omental sites. Int J Gyn Path 30: 366–371. doi: 10.1097/pgp.0b013e31820d20ba
[22]
Rosen DG, Wang L, Atkinson JN, Yu Y, Lu KH, et al. (2005) Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol Oncol 99: 267–277. doi: 10.1016/j.ygyno.2005.06.040
[23]
Souhami RL, Beverley PC, Bobrow LG, Ledermann JA (1991) Antigens of lung cancer: results of the second international workshop on lung cancer antigens. J Natl Cancer Inst 83: 609–612. doi: 10.1093/jnci/83.9.609
[24]
Marks A, Sutherland DR, Bailey D, Iglesias J, Law J, et al. (1999) Characterization and distribution of an oncofetal antigen (M2A antigen) expressed on testicular germ cell tumours. Br J Cancer 80: 569–578.
